Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 1/2 3Phase 3 2

Status

Completed 3

Sponsor Class

OTHER 6INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 1Lymphoid 1Genitourinary 1Dermatologic 1

Conditions

Neoplasms 1Neoplasm Metastasis 1Lymphoma, T-Cell, Cutaneous 1Lymphoma 1Carcinoma, Renal Cell 1Carcinoma 1

Interventions

pembrolizumab 242Carboplatin 137Nivolumab 132Gemcitabine 127Paclitaxel 116Cisplatin 105Cyclophosphamide 97Bevacizumab 93Dexamethasone 78Injections 75Pemetrexed 71Docetaxel 71Fluorouracil 68Capecitabine 65Rituximab 61Cetuximab 61atezolizumab 59130-nm albumin-bound paclitaxel 59Oxaliplatin 58Leucovorin 57Ipilimumab 54fludarabine 50Lenalidomide 47Azacitidine 40Irinotecan 39venetoclax 38Fulvestrant 38Albumin-Bound Paclitaxel 36Prednisone 35Trastuzumab 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × INDUSTRY × ProMune × Clear all
NCT00031278 2011-05-30

Safety And Efficacy Study Of The Combination Of CpG 7909 And Herceptin In Patients With Metastatic Breast Cancer

Pfizer

Phase 1/2 Completed
12 enrolled
Tumor-Agnostic

Carcinoma, Neoplasm Metastasis, Neoplasms

NCT00043407 2009-02-12

CPG 7909 in Patients Wih Stage IV Renal Cell Cancer

Pfizer

Phase 1/2 Completed
42 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT00043420 2009-02-12

CPG 7909 in Patients With Cutaneous T-Cell Lymphoma

Pfizer

Phase 1/2 Completed
42 enrolled
DermatologicLymphoid

Lymphoma, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡